Diploma (LON:DPLM) Reaches New 12-Month High at $3,870.00

Diploma PLC (LON:DPLMGet Free Report)’s stock price hit a new 52-week high during mid-day trading on Friday . The company traded as high as GBX 3,870 ($48.62) and last traded at GBX 3,843.28 ($48.28), with a volume of 79681 shares changing hands. The stock had previously closed at GBX 3,848 ($48.34).

Analysts Set New Price Targets

A number of equities analysts have weighed in on DPLM shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 4,500 ($56.53) target price on shares of Diploma in a research report on Tuesday. Berenberg Bank increased their price objective on shares of Diploma from GBX 3,800 ($47.74) to GBX 4,400 ($55.28) and gave the company a “buy” rating in a research report on Thursday, March 28th. Finally, Shore Capital reaffirmed a “buy” rating on shares of Diploma in a research report on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 3,712.50 ($46.64).

View Our Latest Analysis on DPLM

Diploma Trading Up 0.5 %

The firm has a market capitalization of £5.18 billion, a P/E ratio of 4,228.57, a P/E/G ratio of 2.82 and a beta of 0.73. The company has a current ratio of 2.06, a quick ratio of 0.80 and a debt-to-equity ratio of 44.05. The stock has a 50 day simple moving average of GBX 3,554.44 and a 200-day simple moving average of GBX 3,384.33.

About Diploma

(Get Free Report)

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.

Read More

Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.